We used chromatin immunoprecipitation sequencing (ChIP‐seq) to define their genome binding patterns, immunofluorescence analysis to analyze co‐localization and then evaluated the impact of BRD4 inhibition or degradation on FET sarcoma cells. The gene discussed is BRD4; the disease is sarcoma.